This is a CancerMoonshot. China is moving forward with the first ever human trials to use the CRISPR–Cas9 gene-editing technique to treat lung cancer in August 2016. Similar to the CAR-T Immunotherapy approach, Chinese scientists will extract T cells from NSCLC patients blood and use CRISPR to “knock out” a gene that encodes the PD-1 protein. The gene-edited cells will then be multiplied in the lab and re-introduced into the patient’s bloodstream. The engineered cells will circulate and hopefully attack the cancer. Editing the gene with CRISPR to block PD-1 may be a more efficient and powerful method than using checkpoint inhibitors like nivolumab (Opdivo) or pembrolizumab (Keytruda). This is one to watch!! https://www.statnews.com/2016/…/21/crispr-experiment-humans/ http://www.nature.com/…/chinese-scientists-to-pioneer-first…


This is a CancerMoonshot. China is moving forward with the first ever human trials to use the CRISPR–Cas9 gene-editing technique to treat lung cancer in August 2016. Similar to the CAR-T Immunotherapy approach, Chinese scientists will extract T cells from NSCLC patients blood and use CRISPR to “knock out” a gene that encodes the PD-1 protein. The gene-edited cells will then be multiplied in the lab and re-introduced into the patient’s bloodstream. The engineered cells will circulate and hopefully attack the cancer.
Editing the gene with CRISPR to block PD-1 may be a more efficient and powerful method than using checkpoint inhibitors like nivolumab (Opdivo) or pembrolizumab (Keytruda). This is one to watch!!
https://www.statnews.com/2016/…/21/crispr-experiment-humans/
http://www.nature.com/…/chinese-scientists-to-pioneer-first…

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s